Our Science

Our lead development candidate is:
GOA26

Imagine Naloxone for Alcohol

 

GOA26 is a first-in-class injectable two-stage combination drug candidate for treating alcohol poisoning and intoxication by rapidly and safely eliminating alcohol and its toxic metabolites.

Stage 1:

Stage 2:

Enzyme metabolizes ethanol to acetaldehyde

Chemical formulation sequesters acetaldehyde

Results in Preclinical Models

In IND-enabling studies in porcine models, GOA26 lowered blood alcohol concentrations by over 61% at 20 minutes post-administration compared with the control group.

61% Alcohol Eliminated

GOA26 Delivery Technologies

GOA26 is being developed initially for intravenous administration in acute-care medical settings, followed by plans for self-administered formulations for broad consumer use.

  • Intravenous
  • Subcutaneous
  • Inhaler
  • Transdermal
  • Nasal spray

Join the mission.

Invest

Stay Up to Date with GOA Therapeutics

Get the latest company news, scientific updates, clinical milestones and announcements from GOA Therapeutics.